Deyu Fu

Deyu Fu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2022 in Pharmaceutical Biology
Verified
Journal Article
Open access
BLBo Lu
Bo Lu
JLJianhua Li
Jianhua Li
MGMingTai Gui
MingTai Gui
LYLei Yao
Lei Yao
MFMingsong Fan
Mingsong Fan
DFDeyu Fu
Deyu Fu
Salvianolic acid B (SalB) can attenuate myocardial ischemia/reperfusion (I/R) injury, but the mechanisms are not entirely known.Our study investigates if SalB protects cardiomyocytes against I/R in...

1 January 2021 in Pharmaceutical Biology
Verified
Journal Article
Open access
BLBo Lu
Bo Lu
JXJun Xie
Jun Xie
DFDeyu Fu
Deyu Fu
XCXiaozhe Chen
Xiaozhe Chen
MZMingyi Zhao
Mingyi Zhao
JLJianhua Li
Jianhua Li
HuoXue QianYang QuTan Recipe (HQQR) is used to manage hypertension and cardiac remodelling, but the mechanism is elusive.To determine the mechanism of HQQR on obesity hypertension (OBH)-related myo...

1 June 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
YLYunfeng Li
Yunfeng Li
YMYulong Ma
Yulong Ma
LYLei Yao
Lei Yao
JLJianhua Li
Jianhua Li
XZXunjie Zhou
Xunjie Zhou
DFDeyu Fu
Deyu Fu
The global epidemic of obesity and diabetes imposes a significant strain on healthcare systems, substantially elevating the risk of vascular dysfunction and its associated complications. Astragaloside IV (AS-IV) and berberine (BBR) have demonstrated considerable promise in addressing vascular issues linked to these conditions. This review examines the mechanisms driving their vascular protective effects, drawing on evidence from preclinical studies to compare and contrast their modes of action. It explores both the unique and overlapping pathways through which they mitigate the complications of obesity and diabetes. A thorough analysis of their therapeutic potential highlights promising preclinical data and its clinical implications. However, challenges remain, such as enhancing the bioavailability of AS-IV and BBR and translating preclinical findings into robust clinical trials. This synthesis provides critical insights for advancing research and practical approaches in managing vascular dysfunction associated with obesity and diabetes.

14 October 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
MGMingtai Gui
Mingtai Gui
LYLei Yao
Lei Yao
BLBo Lu
Bo Lu
JWJing Wang
Jing Wang
XZXunjie Zhou
Xunjie Zhou
DFDeyu Fu
Deyu Fu
Continuous and irreversible cardiac hypertrophy can induce cardiac maladaptation and cardiac remodeling, resulting in increased risk of developing cardiovascular diseases. The present study was conducted to investigate the therapeutic effect of Huoxue Qianyang Qutan recipe (HQQR) on angiotensin II (Ang II)‑induced cardiomyocyte hypertrophy. Primary cardiomyocytes were isolated from the cardiac tissue of neonatal rats, followed by flow cytometry detection to confirm the proportion of primary cardiomyocytes. Cell Counting Kit‑8 assay and immunofluorescence detection were performed to examine the effect of Ang II and HQQR on cardiomyocyte hypertrophy. Reactive oxygen species (ROS) and a series of metabolic indicators were quantified to investigate the effect of HQQR on Ang II‑induced cardiomyocyte hypertrophy. Mitochondrial electron transport chain complex activity and related coding gene expression were determined to explore the effect of HQQR on mitochondrial function. HQQR significantly inhibited Ang II‑induced cardiomyocyte hypertrophy and restored Ang II‑induced ROS accumulation, metabolic indicators, and membrane potential levels. HQQR also regulated the mitochondrial function related to the sirtuin 1 pathway in Ang II‑induced cardiomyocytes by increasing the activity of the mitochondrial electron transport chain complex and affecting the expression of genes encoding mitochondrial electron transport chain complex subunits. HQQR could alleviate Ang II‑induced cardiomyocyte hypertrophy by modulating oxidative stress, accumulating ROS and increasing mitochondrial electron transport chain activity.

22 July 2025 in Journal of Cardiovascular Nursing
Verified
Journal Article
Closed access
YLYunfeng Msc Li
Yunfeng Msc Li
YMYulong Ma
Yulong Ma
XZXunjie Zhou
Xunjie Zhou
LYLei Yao
Lei Yao
JLJianhua Li
Jianhua Li
DFDeyu Fu
Deyu Fu
Background: Inflammation plays a significant role in the development of hypertension and obesity, and specific dietary patterns can influence systemic inflammation. However, the link between dietary inflammatory potential and obesity-related hypertension (ORH) remains unclear. Objective: In this study, our aim was to evaluate the association between the Dietary Inflammatory Index (DII) and ORH using data from the National Health and Nutrition Examination Survey 1999 to 2020. Methods: The DII, calculated from a 24-hour dietary recall questionnaire, was used to assess dietary inflammatory potential. Blood pressure was measured by trained examiners, and obesity was defined as a body mass index of 30 kg/m 2 or higher. Weighted logistic regression analysis was used to explore the association between DII and ORH. Results: Individuals with ORH exhibited a higher DII (1.58 ± 0.03) compared with hypertensive (1.41 ± 0.03) and nonhypertensive (1.34 ± 0.03) individuals. Weighted logistic regression indicated a significant positive correlation between DII and ORH. In the fully adjusted model, higher DII scores were associated with increased odds of ORH (Q2, 1.12 [0.99–1.27]; Q3, 1.34 [1.19–1.51]; Q4, 1.42 [1.26–1.61]). In addition, all-cause mortality risk significantly increased with higher DII levels in the population with ORH. Notably, the association between DII and ORH was more pronounced among non-Hispanic White individuals ( p for interaction < .05). Conclusions: Higher DII is associated with increased prevalence of ORH, as well as all-cause mortality, with non-Hispanic White individuals being more susceptible to the influence of proinflammatory diets.